Table 1 Demographics and baseline characteristics
Characteristic | All patients (n = 62) |
|---|---|
Age, years, median (range) | 56 (23–73) |
Sex, n (%) | |
Male | 36 (58.1) |
Female | 26 (41.9) |
BMI, kg/m2, mean ± SD | 22.8 ± 3.2 |
Primary tumor location, n (%) | |
Colon | 40 (64.5) |
Rectum | 22 (35.5) |
Tumor site, n (%) | |
Left or rectum | 40 (64.5) |
Right | 22 (35.5) |
MSS/pMMR, n (%) | 62 (100.0) |
Surgery on primary tumor, n (%) | |
Radical surgery | 26 (41.9) |
Palliative surgery | 13 (21.0) |
Diagnostic procedure | 2 (3.2) |
Previous (neo) adjuvant therapy, n (%) | 12 (19.4) |
ECOG performance status, n (%) | |
0 | 17 (27.4) |
1 | 45 (72.6) |
Metastasis sites, n (%) | |
Liver | 43 (69.4) |
Peritoneum | 12 (19.4) |
RAS gene status, n (%)a | |
Wild-type | 24 (38.7) |
Mutant-type | 36 (58.1) |
BRAF gene status, n (%)a | |
Wild-type | 47 (75.8) |
Mutant-type | 4 (6.5) |
RAS/BRAF, n (%)a | |
RAS and BRAF wild-type | 11 (17.7) |
RAS or BRAF mutant-type | 40 (64.5) |
PD-L1 expression, n (%)a,b | |
Positive (TPS ≥ 1% or CPS ≥ 1) | 33 (53.2) |
Negative | 26 (41.9) |
TGF-β1, n (%)a | |
Positive | 10 (16.1) |
Negative | 9 (14.5) |
pSMAD 2/3 expression, n (%)a | |
≥80% | 10 (16.1) |
<80% | 9 (14.5) |
